|Videos|July 2, 2013
Episode 14 - Concerns about Rising Costs of Treatment
Advertisement
Episodes in this series
During this segment, the panelists discuss their concerns about the rising costs of drugs currently available to treat multiple sclerosis (MS).
Gary M. Owens, MD, states that it is unclear why drug prices continue to rise, especially when certain options have been available for years. Dr Owens further explains there is no single formula to determine a return on investment for newer agents.
Because the drugs to treat MS are extremely expensive and difficult for patients to afford, Dr Owens and Leslie Fish, PharmD, suggest that when reviewing and negotiating the price of a therapy option, there is a need for transparency and comparative effectiveness.
Advertisement
Related to this article
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
A systematic review found vitamin D did not consistently reduce MS relapse rates, though some studies reported lower MRI lesion activity.
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.
Financial toxicity affects nearly half of adults with sarcoma in a US cohort, and the authors call for routine screening to guide targeted support.
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
4
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
5